Salmeterol/fluticasone propionate - Adamis Pharmaceuticals Corporation

Drug Profile

Salmeterol/fluticasone propionate - Adamis Pharmaceuticals Corporation

Alternative Names: APC 5000 DPI; APC-5000; Fluticasone propionate/salmeterol - Adamis Pharmaceuticals; Salmeterol-xinafoate/fluticasone-propionate

Latest Information Update: 05 Aug 2016

Price : $50

At a glance

  • Originator Adamis Pharmaceuticals Corporation
  • Class Androstadienes; Antiallergics; Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Phenethylamines; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Lipocortin synthesis agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 03 Aug 2016 Adamis has European patent for salmeterol/fluticasone propionate using DPI
  • 03 Aug 2016 Adamis received notice of patent allowance for salmeterol/fluticasone propionate using DPI in USA
  • 09 Mar 2015 Phase-II clinical trials in Asthma in USA and Chronic obstructive pulmonary disease (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top